Scott Smith, DO
Dermatology · Spokane Valley, WANPI 1992803811
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,750 of the $9,476 with a category attached, or 71.2%. Incyte Corporation accounts for 72.1% of it on its own, with 14 other manufacturers making up the rest.
Across 136 payments — averaging $69.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$7K
- AbbVie$916
- Lilly USA, LLC$457
- UCB, Inc.$395
- Johnson & Johnson$256
- Novartis$206
- plus $416 from 9 others
What the payments were for
- Consulting fees$6,75071%
- Food & beverage$2,62728%
- Education$991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 7 | $6,830 |
| AbbVie(2 entities) | 57 | $916 |
| Lilly USA, LLC | 23 | $457 |
| UCB, Inc. | 11 | $395 |
| Johnson & Johnson | 12 | $256 |
| Novartis | 10 | $206 |
| Amgen | 4 | $101 |
| Convatec Inc. | 1 | $69 |
| Revance Therapeutics, Inc. | 2 | $56 |
| Bristol Myers Squibb | 3 | $53 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $48 |
| Galderma Laboratories, L.p. | 2 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,476 in reported general payments places this provider in the 85th percentile of 323 dermatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 176 | $7,228 |
| Calcipotriene | 21 | $2,830 |
| Ketoconazole | 142 | $2,649 |
| Imiquimod | 62 | $2,109 |
| Clindamycin Phosphate | 45 | $1,218 |
| Triamcinolone Acetonide | 84 | $1,122 |
| ValacyclovirValacyclovir Hcl | 21 | $746 |
| Fluocinonide | 24 | $538 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 13 | $412 |
| Minocycline Hcl | 26 | $242 |
| Hydroxyzine Hcl | 11 | $205 |
| Levocetirizine Dihydrochloride | 17 | $180 |
| Cephalexin | 20 | $137 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Spokane Valley
- Paul DunnSpokane Valley$28K
- Clive LiuBellevue$2.9M
- Vivian ShiSeattle$971K
- William WerschlerSpokane$948K
- Daniel LevyBonney Lake$541K
- Daniel SugaiBellevue$302K
- Ting-Lin YangBellingham$124K
- James CollyerSeattle$115K
- Cameron ChesnutSpokane$93K
- Alison YoungSeattle$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.